bit.bio is a technology company.
bit.bio has raised $142.5M across 3 funding rounds.
bit.bio has raised $142.5M in total across 3 funding rounds.
bit.bio has raised $142.5M in total across 3 funding rounds.
bit.bio's investors include BDC Venture Capital, BoxOne Ventures, SVG Ventures-THRIVE, W Fund, Boundary Capital Partners LLP, Mogrify, Sana Capital, Jonathan Milner.
bit.bio is a synthetic biology company that develops proprietary technologies to precisely reprogram human induced pluripotent stem cells (iPSCs) into consistent, mature cell types for research, drug discovery, and cell therapy.[1][2][5] Its core products, branded as ioCells, include nerve cells, immune cells, muscle cells, and disease models, powered by the patented opti-ox™ platform that enables deterministic cell programming at industrial scale.[2][3][5][7] The company serves researchers, pharma companies, and therapy developers by solving the challenge of inconsistent, low-yield stem cell differentiation, democratizing access to high-quality human cells to accelerate biomedical innovation and lower cell therapy costs.[1][2][6]
Founded as a University of Cambridge spinout in 2016, bit.bio has raised ~$225M from investors like Arch Venture, Foresite Capital, and Tencent, launched 17 new products in 2023, and joined the UK's Future Fifty program, signaling strong growth momentum toward public markets and clinical translation.[2][3]
bit.bio was founded in 2016 by Dr. Mark Kotter, a stem cell biologist from the University of Cambridge, who applied an engineering mindset to synthetic and stem cell biology to create efficient cell reprogramming technologies.[1][2][4] The name "bit.bio" reflects the intersection of coding (bits as building blocks of code) and biology (cells as building blocks of life), capturing Kotter's vision of precisely "coding" human stem cells.[1]
The idea emerged from Kotter's research frustrations with traditional stem cell differentiation—mimicking embryonic development via chemical stimuli—which yields inconsistent results due to epigenetic variability.[5] Early traction came from developing opti-ox™, a safe-harbor gene-targeting system using inducible transcription factors identified via high-throughput screens and machine learning.[2][5] Pivotal moments include raising significant funding, expanding leadership with CEO Przemek Obloj and chair Dr. Hermann Hauser, and board additions like Nobel laureate Sir Gregory Winter.[2][4]
bit.bio stands out through its end-to-end cell coding platform, contrasting traditional methods with precision engineering:
These enable cost reductions in cell therapies by up to two orders of magnitude while supporting research-to-clinic translation.[2][6]
bit.bio rides the synthetic biology and advanced therapies wave, where precise cellular reprogramming addresses key bottlenecks in drug discovery (e.g., poor human cell models) and cell/gene therapy manufacturing (scalability for widespread use).[1][2][6] Timing is ideal amid booming iPSC tech, AI-driven biology, and investor focus on scalable platforms—evidenced by $225M funding and Future Fifty selection amid UK tech growth.[2][3]
Market forces like rising demand for human-relevant models (over animal testing), cell therapy market projected to explode, and regulatory pushes for consistent manufacturing favor bit.bio.[6] It influences the ecosystem by partnering with giants (Bayer's BlueRock, Ginkgo), expanding functional genomics tools (2025 gene activation cells launch), and enabling "off-the-shelf" therapies, shifting focus from cell scarcity to broad patient access.[3][6][7]
bit.bio is poised to lead precision cell programming, with near-term catalysts including therapeutics pipeline advances, more ioCells launches, and public market transition via Future Fifty networks.[3] Trends like AI-biology convergence, cost-pressured therapies, and global SynBio investment will propel growth, potentially dominating scalable iPSC-derived cells.
As it scales from research tools to curative medicines, bit.bio could redefine human health by making consistent cells ubiquitous—echoing its founding hook of rewriting health, one cell at a time.[7]
bit.bio has raised $142.5M across 3 funding rounds. Most recently, it raised $100.0M Series B in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $100.0M Series B | BDC Venture Capital, BoxOne Ventures, SVG Ventures-THRIVE, W Fund | |
| Jun 1, 2020 | $42.0M Series A | BDC Venture Capital, BoxOne Ventures, SVG Ventures-THRIVE, W Fund | |
| Nov 1, 2017 | $460K Seed | Boundary Capital Partners LLP, Mogrify, Sana Capital, Jonathan Milner |